Clinical trial of cisplatin-conjugated gelatin microspheres for patients with hepatocellular carcinoma

Japanese Journal of Radiology

Volumn 30, Issue 1, 2012, Pages 62-68

  Toyama, Tetsuya ^a   Nitta, Norihisa ^a   Ohta, Shinichi ^a   Tanaka, Toyohiko ^a   Nagatani, Yukihiro ^a   Takahashi, Masashi ^a   Murata, Kiyoshi ^a   Shiomi, Hisanori ^a   Naka, Shigeyuki ^a   Kurumi, Yoshimasa ^a   Tani, Tohru ^a   Tabata, Yasuhiko ^b  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Cisplatin conjugated gelatin microspheres; Drug delivery system; Hepatocellular carcinoma; Liver; Transarterial embolization chemoembolization

Indexed keywords

CISPLATIN; MICROSPHERE; ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG CARRIER; GELATIN; IOPAMIDOL;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BONE MARROW TOXICITY; CANCER STAGING; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FEVER; DRUG FORMULATION; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; MALE; NAUSEA AND VOMITING; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT RESPONSE; IMAGE QUALITY; LIVER TUMOR; METHODOLOGY; MIDDLE AGED; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CISPLATIN; CONTRAST MEDIA; DRUG CARRIERS; FEMALE; FOLLOW-UP STUDIES; GELATIN; HUMANS; IOPAMIDOL; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; RADIOGRAPHIC IMAGE ENHANCEMENT; TREATMENT OUTCOME;

EID: 84862332456     PISSN: 18671071     EISSN: 1867108X     Source Type: Journal    
DOI: 10.1007/s11604-011-0010-2     Document Type: Article

References (26)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153-6. (Pubitemid 32911406)
2. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752-63. (Pubitemid 351615415)
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-36. (Pubitemid 43112690)
4. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25:181-200. (Pubitemid 40781071)
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90.
6. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429-42. (Pubitemid 36152543)
7. Gunven P. Liver embolizations in oncology: a review. Part I. Arterial (chemo)embolizations. Med Oncol. 2008;25:1-11.
8. Brown DB, Pilgram TK, Darcy MD, Fundakowski CE, Lisker-Melman M, Chapman WC, et al. Hepatic arterial chemoemboli-zation for hepatocellular carcinoma: comparison of survival rates with different embolic agents. J Vasc Interv Radiol. 2005;16: 1661-6. (Pubitemid 44431163)
9. Grosso M, Vignali C, Quaretti P, Nicolini A, Melchiorre F, Gallarato G, et al. Transarterial chemoembolization for hepato-cellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicentre study. Cardiovasc Intervent Radiol. 2008;31:1141-9.
10. Malagari K, Alexopoulou E, Chatzimichail K, Hall B, Koskinas J, Ryan S, et al. Transcatheter chemoembolization in the treat-ment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead. Abdom Imag-ing. 2008;33:512-9.
11. Konishi M, Tabata Y, Kariya M, Hosseinkhani H, Suzuki A, Fukuhara K, et al. In vivo anti-tumor effect of dual release of cisplatin and adriamycin from biodegradable gelatin hydrogel. J Control Release. 2005;103:7-19. (Pubitemid 40248557)
12. Konishi M, Tabata Y, Kariya M, Suzuki A, Mandai M, Nanbu K, et al. In vivo anti-tumor effect through the controlled release of cisplatin from biodegradable gelatin hydrogel. J Control Release. 2003;92:301-13. (Pubitemid 38366153)
13. Ohta S, Nitta N, Sonoda A, Seko A, Tanaka T, Takahashi M, et al. Cisplatin-conjugated degradable gelatin microspheres: fundamental study in vitro. Br J Radiol. 2009;82:380-5.
14. Nitta N, Ohta S, Tanaka T, Takazakura R, Toyama T, Sonoda A, et al. An initial clinical study on the efficacy of cisplatin-releasing gelatin microspheres for metastatic liver tumors. Eur J Radiol. 2009;71:519-26.
15. Ohta S, Nitta N, Sonoda A, Seko A, Tanaka T, Takahashi M, et al. Prolonged local persistence of cisplatin-loaded gelatin microspheres and their chemoembolic anti-cancer effect in rab-bits. Eur J Radiol. 2009;72:534-40.
16. Tabata Y, Hijikata S, Muniruzzaman M, Ikada Y. Neovascular-ization effect of biodegradable gelatin microspheres incorporat-ing basic fibroblast growth factor. J Biomater Sci Polym Ed. 1999;10:79-94. (Pubitemid 29097233)
17. Tabata Y, Uno K, Ikada Y, Muramatsu S. Potentiation of anti-tumor activity of macrophages by recombinant interferon alpha A/D contained in gelatin microspheres. Jpn J Cancer Res. 1988;79:636-46.
18. Hong L, Miyamoto S, Hashimoto N, Tabata Y. Synergistic effect of gelatin microspheres incorporating TGF-beta1 and a physical barrier for fibrous tissue infiltration on skull bone formation. J Biomater Sci Polym Ed. 2000;11:1357-69. (Pubitemid 32208315)
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
20. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
21. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL confer-ence. European Association for the study of the liver. J Hepatol. 2001;35:421-30. (Pubitemid 32844200)
22. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176-81. (Pubitemid 36962641)
23. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734-9. (Pubitemid 34607087)
24. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoemb-olization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164-71. (Pubitemid 34454013)
25. Ozeki M, Tabata Y. In vivo degradability of hydrogels prepared from different gelatins by various cross-linking methods. J Bio-mater Sci Polym Ed. 2005;16:549-56.
26. Ono Y, Yoshimasu T, Ashikaga R, Inoue M, Shindou H, Fuji K, et al. Long-term results of lipiodol-transcatheter arterial emboli-zation with cisplatin or doxorubicin for unresectable hepatocel-lular carcinoma. Am J Clin Oncol. 2000;23:564-8. (Pubitemid 32429101)